Futureproofing Biosimilars and Expanding Patient Access

Where

Virtual

When

{{getUserDateTimezone("1726765200").singleDate}}
{{getUserDateTimezone("1726765200").time}} - {{getUserDateTimezone("1726767000").time}} {{getClientTimezoneName()}}

About

Biosimilars have recently seen increased momentum in the United States, but uptake barriers remain, limiting the potential for more patients to benefit from these life-changing, lower-cost treatment options. Join Sandoz’s Dr. Sonia T. Oskoeui and the FDA’s Dr. Sarah Yim to discuss the U.S. biosimilars market, the value biosimilars provide to patients, how these medicines fit into the health care system — and what needs to be done to advance adoption.

Moderator

Jesse McQuarters, Branded Content Editor at STAT

Speakers

Sonia T. Oskouei, PharmD, Vice President, US Head of Biosimilars, Sandoz

As Vice President and U.S. Head of Biosimilars, Dr. Sonia T. Oskouei focuses on maximizing the value of biosimilars to enhance patient access to critical therapies and lower the costs of high-quality care. Dr. Oskouei is an established thought leader with extensive expertise in enabling biosimilar adoption.

Sarah Yim, MD, Director, Office of Therapeutic Biologics & Biosimilars, CDER’s Office of New Drugs, FDA

As the Director of the Office of Therapeutic Biologics and Biosimilars, Dr. Sarah Yim shares responsibility for ensuring consistency in the scientific and regulatory approach for development programs related to proposed biosimilar products and therapeutic biologics.